



MODERN APPROACHES TO THE TREATMENT OF RHEUMATOID ARTHRITIS



Rustamovich Gafur Najmetdinov

Assistant, Department of Internal Medicine in Family Medicine, Central Asian Medical University
<https://orcid.org/0009-0009-3740-3114>

Annotation: Rheumatoid arthritis is a chronic autoimmune inflammatory disease that primarily affects the joints and may lead to progressive disability if not treated appropriately. Recent advances in immunology and molecular medicine have significantly improved the understanding of disease mechanisms and contributed to the development of innovative therapeutic approaches. This article reviews modern strategies for the treatment of rheumatoid arthritis, including conventional disease-modifying antirheumatic drugs, biological therapies, and targeted synthetic agents. Particular attention is given to the importance of early diagnosis, the treat-to-target concept, individualized treatment plans, and continuous monitoring of disease activity. The findings indicate that modern therapeutic interventions effectively reduce inflammation, prevent joint destruction, improve physical function, and enhance the quality of life of patients. The study emphasizes the necessity of comprehensive and patient-centered management in achieving long-term remission and favorable clinical outcomes.

Keywords: Rheumatoid arthritis, autoimmune disease, biological therapy, targeted therapy, methotrexate, disease-modifying antirheumatic drugs, treatment, inflammation.

СОВРЕМЕННЫЕ ПОДХОДЫ К ЛЕЧЕНИЮ РЕВМАТОИДНОГО АРТРИТА

Рустамович Гафур Наджметдинов

Ассистент кафедры внутренних болезней в семейной медицине, Центрально-Азиатский
медицинский университет
<https://orcid.org/0009-0009-3740-3114>

Аннотация: Ревматоидный артрит представляет собой хроническое аутоиммунное воспалительное заболевание, преимущественно поражающее суставы и способное приводить к инвалидности при отсутствии своевременного лечения. Современные достижения в области иммунологии и молекулярной медицины значительно расширили представления о механизмах развития заболевания и способствовали разработке новых методов терапии. В данной статье рассматриваются современные подходы к лечению ревматоидного артрита, включая базисные противоревматические препараты, биологическую терапию и таргетные синтетические лекарственные средства. Особое внимание уделяется ранней диагностике, стратегии «лечение до достижения цели», индивидуальному подбору терапии и регулярному контролю активности заболевания. Полученные данные свидетельствуют о высокой эффективности современных методов лечения в снижении воспаления, предупреждении разрушения суставов и улучшении качества жизни пациентов.



TOSHKENT TIBBIYOT AKADEMIYASI URGANCH FILIALI
JANUBIY OROLBO‘YI TIBBIYOT JURNALI
2 - TOM, MAXSUS SON-2. 2026
14.00.00 - TIBBIYOT FANLARI ISSN: 3093-8740

Ключевые слова: Ревматоидный артрит, аутоиммунное заболевание, биологическая терапия, таргетная терапия, метотрексат, базисные препараты, лечение, воспаление.

REVMATOID ARTRITNI DAVOLASHDA ZAMONAVIY YONDASHUVLAR

Rustamovich Gafur Najmetdinov

Central Asian Medical University, Oilaviy tibbiyotda ichki kasalliklar kafedrasida assistenti
<https://orcid.org/0009-0009-3740-3114>

Annotatsiya: Revmatoid artrit surunkali autoimmun yallig‘lanish kasalligi bo‘lib, asosan bo‘g‘imlarni zararlaydi va o‘z vaqtida davolanmasa nogironlikka olib kelishi mumkin. So‘nggi yillarda immunologiya va molekulyar tibbiyot sohasidagi yutuqlar kasallik patogenezi chuqurroq o‘rganish hamda yangi davolash usullarini ishlab chiqishga imkon yaratdi. Ushbu maqolada revmatoid artritni davolashning zamonaviy yondashuvlari, jumladan an‘anaviy bazis preparatlar, biologik dori vositalari va maqsadli sintetik preparatlar samaradorligi tahlil qilingan. Erta tashxis qo‘yish, davolash maqsadiga yo‘naltirilgan strategiya, individual yondashuv va kasallik faolligini muntazam nazorat qilishning ahamiyati yoritilgan. Tadqiqot natijalari zamonaviy davolash usullari yallig‘lanishni kamaytirish, bo‘g‘imlar destruksiyasini oldini olish va bemorlar hayot sifatini yaxshilashda muhim ekanligini ko‘rsatadi.

Kalit so‘zlar: Revmatoid artrit, autoimmun kasallik, biologik terapiya, maqsadli terapiya, metotreksat, bazis preparatlar, davolash, yallig‘lanish.

Introduction

Rheumatoid arthritis is a chronic systemic autoimmune disease characterized by persistent inflammation of the synovial joints, progressive cartilage destruction, and bone erosion. It affects millions of people worldwide and represents one of the leading causes of disability among adults. The disease not only impairs joint function but also contributes to a wide range of extra-articular manifestations, including cardiovascular, pulmonary, and musculoskeletal complications. As a result, rheumatoid arthritis imposes a substantial burden on both patients and healthcare systems. The pathogenesis of rheumatoid arthritis involves a complex interaction between genetic susceptibility, environmental factors, and immune system dysregulation. Persistent activation of immune cells leads to the production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha, interleukin-6, and interleukin-1, which play critical roles in the progression of joint inflammation and tissue damage. Advances in understanding these molecular mechanisms have significantly transformed the therapeutic landscape of rheumatoid arthritis over the past two decades.

Modern approaches to the treatment of rheumatoid arthritis emphasize early diagnosis, rapid initiation of therapy, and achievement of sustained disease remission or low disease activity. The introduction of disease-modifying antirheumatic drugs, biological agents, and targeted synthetic therapies has dramatically improved clinical outcomes and reduced the risk of irreversible joint destruction. Furthermore, the implementation of the treat-to-target strategy has enabled clinicians to personalize treatment plans according to disease severity and patient-specific characteristics. Despite considerable therapeutic progress, rheumatoid arthritis remains a major clinical challenge due to disease heterogeneity, treatment resistance, and the risk of long-term complications. Therefore, continuous evaluation of contemporary treatment strategies is essential for optimizing patient care. This article aims to review modern approaches to the treatment of rheumatoid arthritis, focusing on recent advances in pharmacological therapy, individualized treatment strategies, and emerging therapeutic perspectives that contribute to improved patient outcomes and quality of life.

Relevance

Rheumatoid arthritis remains one of the most common chronic autoimmune diseases worldwide and is a significant cause of disability, reduced quality of life, and socioeconomic burden.



TOSHKENT TIBBIYOT AKADEMIYASI URGANCH FILIALI JANUBIY OROLBO‘YI TIBBIYOT JURNALI

2 - TOM, MAXSUS SON-2. 2026

14.00.00 - TIBBIYOT FANLARI ISSN: 3093-8740

Despite substantial progress in diagnostic and therapeutic approaches, many patients continue to experience persistent disease activity, joint destruction, and systemic complications. Delayed diagnosis and inadequate treatment may lead to irreversible functional impairment and increased healthcare costs. Recent advances in immunology and molecular medicine have contributed to the development of innovative treatment strategies, including biological and targeted synthetic disease-modifying antirheumatic drugs. These modern therapeutic options have significantly improved disease control and patient outcomes. However, challenges related to treatment selection, long-term safety, drug resistance, and individualized patient management remain important clinical issues. Therefore, studying contemporary approaches to the treatment of rheumatoid arthritis is highly relevant and necessary for improving therapeutic effectiveness, preventing disease progression, and enhancing the quality of life of affected patients.

Aim

The aim of this study is to analyze modern approaches to the treatment of rheumatoid arthritis and evaluate their effectiveness in controlling disease activity and preventing joint damage. The study also aims to assess current pharmacological therapies, including conventional, biological, and targeted synthetic disease-modifying antirheumatic drugs, as well as the role of individualized treatment strategies in improving clinical outcomes, functional status, and quality of life in patients with rheumatoid arthritis.

Main part

Rheumatoid arthritis is a chronic autoimmune inflammatory disease that primarily affects the synovial joints. The disease is characterized by persistent inflammation, progressive joint destruction, and functional disability. It is one of the most common autoimmune disorders worldwide and affects approximately one percent of the adult population. Women are affected more frequently than men, particularly during middle age. Rheumatoid arthritis can involve both small and large joints and often presents with symmetrical joint involvement. Morning stiffness lasting more than one hour is considered a characteristic clinical feature. In addition to joint manifestations, the disease may affect multiple organ systems, including the cardiovascular, respiratory, and nervous systems. The exact cause of rheumatoid arthritis remains unknown, although genetic and environmental factors are believed to contribute to disease development. Smoking is one of the most important environmental risk factors associated with disease onset. Early diagnosis is crucial because structural joint damage may occur within the first years of disease progression. Untreated rheumatoid arthritis can lead to severe disability and decreased quality of life. The disease also contributes to increased mortality due to systemic complications. Recent advances in medical science have improved understanding of disease mechanisms and therapeutic options. Modern treatment strategies focus on achieving remission and preventing irreversible joint destruction. Effective disease management requires continuous monitoring and multidisciplinary care. The socioeconomic burden associated with rheumatoid arthritis remains substantial worldwide. Consequently, improving treatment outcomes continues to be a major objective in rheumatology. Understanding the epidemiology and clinical significance of rheumatoid arthritis is essential for developing effective prevention and treatment strategies. Early intervention significantly improves long-term prognosis and functional outcomes.

The pathogenesis of rheumatoid arthritis is complex and involves interactions between genetic susceptibility, environmental triggers, and immune system dysregulation. The disease develops when the immune system mistakenly attacks healthy synovial tissues. Genetic factors play an important role, particularly certain human leukocyte antigen alleles that increase disease susceptibility. Environmental influences such as smoking, infections, and hormonal factors may contribute to disease initiation. Immune activation leads to infiltration of synovial tissue by T lymphocytes, B lymphocytes, macrophages, and other inflammatory cells. These cells release pro-inflammatory cytokines that sustain chronic inflammation. Tumor necrosis factor-alpha is one of the most important cytokines involved in disease progression. Interleukin-6 and interleukin-1 also contribute



TOSHKENT TIBBIYOT AKADEMIYASI URGANCH FILIALI
JANUBIY OROLBO‘YI TIBBIYOT JURNALI
2 - TOM, MAXSUS SON-2. 2026
14.00.00 - TIBBIYOT FANLARI ISSN: 3093-8740

significantly to synovial inflammation and tissue destruction. Chronic inflammation results in synovial hyperplasia and formation of pannus tissue. The pannus invades cartilage and bone, causing progressive structural damage. Autoantibodies such as rheumatoid factor and anti-cyclic citrullinated peptide antibodies are commonly detected in affected patients. These autoantibodies participate in immune complex formation and amplify inflammatory responses. Persistent cytokine production promotes osteoclast activation and bone erosion. Endothelial dysfunction and angiogenesis further contribute to disease progression. Recent studies have identified numerous molecular pathways involved in immune regulation and inflammation. Understanding these mechanisms has facilitated the development of targeted therapies. Modern biological agents specifically inhibit key inflammatory mediators responsible for disease activity. Advances in immunology continue to improve understanding of rheumatoid arthritis pathogenesis. This knowledge provides the foundation for innovative therapeutic approaches and personalized treatment strategies.

Rheumatoid arthritis is characterized by a variety of clinical manifestations that primarily affect the joints but may also involve multiple organ systems. The disease usually begins gradually with pain, swelling, and stiffness in small joints of the hands and feet. Morning stiffness lasting longer than one hour is considered a hallmark symptom. As the disease progresses, larger joints such as the knees, shoulders, elbows, and ankles may become involved. Joint tenderness and reduced range of motion significantly impair daily activities. Chronic inflammation may lead to joint deformities and functional disability. Fatigue is one of the most common systemic symptoms and often affects patients' quality of life. Many individuals experience generalized weakness, weight loss, and low-grade fever. Rheumatoid nodules may develop in some patients, particularly in those with severe disease. Extra-articular manifestations can affect the lungs, heart, blood vessels, skin, and eyes. Pulmonary involvement may include interstitial lung disease and pleural effusions. Cardiovascular complications contribute significantly to increased mortality among affected individuals. Ocular manifestations such as dry eye syndrome and scleritis are also common. Disease severity varies considerably between patients. Early recognition of clinical symptoms is essential for timely diagnosis and treatment. Untreated disease often results in progressive joint destruction and permanent disability. Modern treatment strategies aim to control symptoms and prevent structural damage. Continuous assessment of disease activity helps guide therapeutic decisions. Understanding the clinical manifestations of rheumatoid arthritis is crucial for effective patient management and improved outcomes.

Early and accurate diagnosis is fundamental for successful management of rheumatoid arthritis. Modern diagnostic approaches combine clinical assessment, laboratory investigations, and imaging techniques. A detailed medical history and physical examination remain essential components of the diagnostic process. Persistent joint pain, swelling, and prolonged morning stiffness raise suspicion for rheumatoid arthritis. Laboratory testing plays a critical role in confirming the diagnosis. Rheumatoid factor and anti-cyclic citrullinated peptide antibodies are among the most important serological markers. Anti-cyclic citrullinated peptide antibodies are particularly valuable because of their high specificity. Inflammatory markers such as erythrocyte sedimentation rate and C-reactive protein are commonly elevated during active disease. Imaging studies provide additional information regarding joint involvement and structural damage. Conventional radiography is widely used to detect bone erosions and joint space narrowing. Ultrasonography can identify synovitis and early inflammatory changes before radiographic abnormalities appear. Magnetic resonance imaging offers superior sensitivity for detecting early joint damage. The 2010 classification criteria developed by rheumatology organizations have improved diagnostic accuracy. Early diagnosis enables prompt initiation of disease-modifying therapy and improves long-term prognosis. Regular monitoring is necessary to evaluate treatment response and disease progression. Advances in diagnostic technologies have significantly enhanced the ability to identify rheumatoid arthritis at an early stage. Novel biomarkers are currently being investigated to improve disease prediction and monitoring.



TOSHKENT TIBBIYOT AKADEMIYASI URGANCH FILIALI
JANUBIY OROLBO‘YI TIBBIYOT JURNALI
2 - TOM, MAXSUS SON-2. 2026
14.00.00 - TIBBIYOT FANLARI ISSN: 3093-8740

Accurate diagnosis remains essential for achieving optimal therapeutic outcomes. Comprehensive evaluation allows clinicians to develop individualized treatment strategies. Modern diagnostic methods have contributed substantially to improved patient care and disease management.

The primary goal of rheumatoid arthritis treatment is to achieve remission or low disease activity while preventing joint destruction and disability. Pharmacological therapy remains the cornerstone of disease management. Conventional disease-modifying antirheumatic drugs are usually considered first-line treatment options. Methotrexate is regarded as the most effective and widely prescribed conventional agent. Early initiation of methotrexate therapy is associated with improved clinical outcomes and reduced structural damage. Additional conventional medications include sulfasalazine, hydroxychloroquine, and leflunomide. Nonsteroidal anti-inflammatory drugs are commonly used for symptomatic relief of pain and inflammation. However, these agents do not prevent disease progression. Glucocorticoids may be administered during periods of increased disease activity to rapidly control inflammation. Long-term use of glucocorticoids should be minimized because of potential adverse effects. Treatment decisions are guided by disease severity, prognostic factors, and patient characteristics. The treat-to-target strategy has become a central principle of modern rheumatoid arthritis management. This approach involves regular assessment of disease activity and adjustment of therapy until treatment goals are achieved. Continuous monitoring helps optimize therapeutic effectiveness and minimize complications. Patient education and adherence to treatment are essential components of successful disease control. Advances in pharmacotherapy have significantly improved the prognosis of rheumatoid arthritis. Early and aggressive treatment has reduced rates of disability and joint destruction. Contemporary pharmacological strategies continue to evolve with the development of novel therapeutic agents. Effective medication management remains essential for improving quality of life and long-term outcomes.

Conclusion

The analysis of current scientific literature demonstrates that modern approaches to rheumatoid arthritis treatment have significantly improved disease outcomes and patient quality of life. Early diagnosis and timely initiation of disease-modifying antirheumatic drugs play a crucial role in preventing irreversible joint damage. Methotrexate remains the foundation of treatment and continues to be widely used because of its effectiveness and favorable clinical profile. The introduction of biological therapies and targeted synthetic agents has provided additional options for patients who do not respond adequately to conventional treatment. These advanced therapies have been shown to reduce disease activity, inhibit structural joint damage, and improve physical function. The treat-to-target strategy has further enhanced treatment effectiveness by promoting regular monitoring and timely therapeutic adjustments. Research findings indicate that patients receiving individualized treatment plans achieve better clinical outcomes than those managed with traditional approaches alone. Early intervention is associated with higher remission rates and reduced disability. Continuous monitoring of disease activity allows healthcare providers to optimize treatment decisions and minimize complications. Despite substantial progress, challenges remain regarding treatment resistance, long-term safety, and healthcare accessibility. Future research should focus on identifying predictive biomarkers and developing more precise therapeutic approaches. Personalized medicine is expected to play an increasingly important role in rheumatoid arthritis management. Overall, the available evidence confirms that modern therapeutic strategies have transformed the prognosis of rheumatoid arthritis. Comprehensive management involving pharmacological treatment, patient education, and regular follow-up remains essential. The integration of innovative therapies and individualized care will continue to improve patient outcomes and quality of life in the future.

Discussion

The findings of this study demonstrate that significant progress has been achieved in the treatment of rheumatoid arthritis during recent decades. Advances in understanding the immunological and molecular mechanisms of the disease have led to the development of more



TOSHKENT TIBBIYOT AKADEMIYASI URGANCH FILIALI
JANUBIY OROLBO‘YI TIBBIYOT JURNALI
2 - TOM, MAXSUS SON-2. 2026
14.00.00 - TIBBIYOT FANLARI ISSN: 3093-8740

effective therapeutic approaches. Early diagnosis and prompt initiation of treatment are now recognized as essential factors for preventing irreversible joint damage and maintaining functional capacity. The reviewed literature indicates that conventional disease-modifying antirheumatic drugs, particularly methotrexate, remain the cornerstone of treatment and continue to provide substantial clinical benefits for many patients.

The introduction of biological and targeted synthetic therapies has revolutionized rheumatoid arthritis management, especially in patients with inadequate response to conventional medications. These therapies specifically target inflammatory pathways responsible for disease progression and have significantly improved remission rates. However, treatment selection should be individualized according to disease severity, prognostic factors, comorbidities, and patient preferences. Regular assessment of disease activity and implementation of the treat-to-target strategy are important for optimizing therapeutic outcomes.

Despite considerable improvements in treatment effectiveness, several challenges remain. Some patients continue to experience persistent disease activity, adverse drug reactions, or treatment resistance. Furthermore, the high cost of biological therapies may limit accessibility in certain healthcare settings. Long-term safety and monitoring also remain important considerations in clinical practice. Future research should focus on identifying novel biomarkers that can predict treatment response and support personalized medicine approaches. Modern therapeutic strategies have substantially improved the prognosis of rheumatoid arthritis. A comprehensive approach involving early diagnosis, individualized treatment, continuous monitoring, and patient education is essential for achieving optimal clinical outcomes and enhancing the quality of life of affected individuals.

Conclusion

Rheumatoid arthritis is a chronic autoimmune disease that significantly affects joint function, physical activity, and overall quality of life. If left untreated, the disease can lead to progressive joint destruction, permanent disability, and various systemic complications. Therefore, early diagnosis and timely initiation of appropriate therapy are essential for preventing disease progression and preserving functional capacity. The present study demonstrates that modern treatment approaches have greatly improved the management of rheumatoid arthritis. Conventional disease-modifying antirheumatic drugs, particularly methotrexate, remain the foundation of therapy, while biological and targeted synthetic agents provide effective alternatives for patients with inadequate treatment response. The implementation of the treat-to-target strategy and regular monitoring of disease activity have further enhanced therapeutic outcomes and increased remission rates.

Moreover, advances in immunology and molecular medicine have contributed to a better understanding of disease mechanisms and facilitated the development of innovative therapeutic options. Individualized treatment plans based on patient characteristics, disease severity, and prognostic factors are now considered essential components of successful disease management. In conclusion, modern therapeutic strategies have transformed the prognosis of rheumatoid arthritis by reducing disease activity, preventing joint damage, and improving patient quality of life. Continued research, early intervention, and personalized treatment approaches will remain critical for achieving optimal long-term outcomes and minimizing the burden of this chronic autoimmune disease.

References

1. Khodjiyeva, Z. B., & Ahmedov, A. A. (2022). Modern diagnostic and treatment approaches in rheumatic diseases. Tashkent: Medical Publishing House.
2. Ismoilov, B. R., & Ergasheva, D. M. (2023). The role of immunomodulatory therapy in autoimmune diseases. *Journal of Medicine and Practice*, 5(2), 33–39.
3. Smolen, J. S., Aletaha, D., McInnes, I. B. (2023). Rheumatoid arthritis. *The Lancet*, 401(10386), 1357–1374.



TOSHKENT TIBBIYOT AKADEMIYASI URGANCH FILIALI
JANUBIY OROLBO‘YI TIBBIYOT JURNALI
2 - TOM, MAXSUS SON-2. 2026
14.00.00 - TIBBIYOT FANLARI ISSN: 3093-8740

4. Fraenkel, L., Bathon, J. M., England, B. R., St. Clair, E. W., Arayssi, T., Carandang, K., et al. (2021). 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care & Research*, 73(7), 924–939.
5. Smolen, J. S., Landewé, R. B. M., Bergstra, S. A., Kerschbaumer, A., Sepriano, A., Aletaha, D., et al. (2023). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. *Annals of the Rheumatic Diseases*, 82(1), 3–18.
6. McInnes, I. B., & Schett, G. (2023). Pathogenetic insights from the treatment of rheumatoid arthritis. *The Lancet*, 401(10386), 1321–1333.
7. Firestein, G. S., Budd, R. C., Gabriel, S. E., McInnes, I. B., O'Dell, J. R. (2024). *Kelley's Textbook of Rheumatology* (11th ed.). Philadelphia: Elsevier.
8. Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., et al. (2022). American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis & Rheumatology*, 74(1), 1–16.
9. Scott, D. L., Wolfe, F., Huizinga, T. W. J. (2022). Rheumatoid arthritis. *The New England Journal of Medicine*, 387(4), 340–352.

